CSIR in the news..

An aggregation of news on the web about CSIR and its laboratories

Nostrum Pharmaceuticals, LLC Licenses Clinical Development and Worldwide Commercialization Rights From IMTECH, India, for Novel, Next-Generation Thrombolytics With Clot Specific Activation and Re-occlusion Prevention Properties

24 November 2010

NEW BRUNSWICK, N.J: Nostrum Pharmaceuticals, LLC (“Nostrum”), a privately held pharmaceuticals company based in New Brunswick, New Jersey, announced today its licensing agreement with Institute of Microbial Technology (“IMTECH”), Chandigarh, India, a research institute under Council of Scientific and Industrial Research (“CSIR”), a Government of India organization.  Pursuant to such agreement, Nostrum will in-license next generation thrombolytics from IMTECH for clinical development and worldwide commercialization.

Nirmal Mulye, Ph.D., President of Nostrum, said, “These novel, next generation thrombolytics are clot specific plasminogen activator proteins, and each one of these molecules has a uniquely different value-added properties such as longer half-life in blood circulation and re-occlusion prevention during heart attack.  Moreover, these unique properties of the molecules will help to effectively mitigate a number of systemic side effects, such as bleeding, usually associated with the prevalent thrombolytic protein molecules in the market today.”  Dr. Mulye further said, “Our collaboration with CSIR is an example of successful public-private partnership.  This is our third collaboration with IMTECH/ CSIR.  Clearly they have been developing world-class technologies and setting an example of pursuing commercially viable innovations.”

These new molecules were invented at IMTECH in the laboratory headed by Girish Sahni, Ph.D., who is also the director of IMTECH.  Dr. Sahni said, “Re-occlusion of the blood vessel after thrombolytics treatment remains one of the main cause for patient death after the heart attack and continues to be both a practical and scientific challenge to reckon with.”  Dr. Sahni added, “My group at IMTECH had been working for a very long time to come up with an approach that will resolve the issue of blood vessel re-occlusion after thrombolytics treatment.  I am glad that one of our new thrombolytic molecules has shown that promise in the laboratory experiments.  Based on these results we are confident that it will develop into a world class drug with a most sought after property of not only clot specificity of activation but also re-occlusion prevention.”  Dr. Sahni further added, “Collaborating with Nostrum over the years has been a very fulfilling experience.  They have demonstrated a true commitment to take forward our collaborations as seen by the remarkable pace at which they have taken forward the development of our first thrombolytic Clot Specific Streptokinase (CSSK).”…..

Read more: http://www.sunherald.com/2010/11/24/2666186/nostrum-pharmaceuticals-llc-licenses.html#ixzz16GJTZG22


Written by csirindia

November 25, 2010 at 9:12 am

Posted in IMTECH

%d bloggers like this: